Cargando…

BCL-X(L) PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS(G12C)-mutated cancers

KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRAS(G12C), was recently approved for the treatment of KRAS(G12C)-mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib and other KRAS(G12C) inhibitors is limited by intrinsic r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Sajid, Wiegand, Janet, Zhang, Peiyi, Hu, Wanyi, Thummuri, Dinesh, Budamagunta, Vivekananda, Hua, Nan, Jin, Lingtao, Allegra, Carmen J., Kopetz, Scott E., Zajac-Kaye, Maria, Kaye, Frederic J., Zheng, Guangrong, Zhou, Daohong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905794/ https://www.ncbi.nlm.nih.gov/pubmed/35260176 http://dx.doi.org/10.1186/s13045-022-01241-3

Ejemplares similares

Co-targeting BCL-X(L) and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice
por: Khan, Sajid, et al.
Publicado: (2023)

Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X(L)–Specific Degrader DT2216
por: Thummuri, Dinesh, et al.
Publicado: (2022)

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)

BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival
por: Champion, Ophélie, et al.
Publicado: (2023)

PROTACs are effective in addressing the platelet toxicity associated with BCL-X(L) inhibitors
por: Zhang, Peiyi, et al.
Publicado: (2020)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

A selective BCL-X(L) PROTAC degrader achieves safe and potent antitumor activity
por: Khan, Sajid, et al.
Publicado: (2019)

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity
por: He, Yonghan, et al.
Publicado: (2020)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

Cellular senescence in lymphoid organs and immunosenescence
por: Budamagunta, Vivekananda, et al.
Publicado: (2021)

2216. Pneumonia in the ICU: Epidemiology and Outcomes
por: Blaha, Michael, et al.
Publicado: (2019)

Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Correction to: Sotorasib: First Approval
por: Blair, Hannah A.
Publicado: (2021)

Inhibition of USP7 activity selectively eliminates senescent cells in part via restoration of p53 activity
por: He, Yonghan, et al.
Publicado: (2020)

CodeBreak 200: Sotorasib Has Not Broken the KRAS(G12C) Enigma Code
por: Zhang, Shannon S, et al.
Publicado: (2023)

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology
por: Burke, Matthew R., et al.
Publicado: (2022)

PROTAC-DB: an online database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2020)

Clinicopathological Concordance in 2216 Cases of Skin Biopsy over One Year: An Indian Experience
por: Malik, Akanksha, et al.
Publicado: (2020)

Senescence-associated hyper-activation to inflammatory stimuli in vitro
por: Budamagunta, Vivekananda, et al.
Publicado: (2021)

Spotlight on Sotorasib (AMG 510) for KRAS(G12C) Positive Non-Small Cell Lung Cancer
por: Zhang, Shannon S, et al.
Publicado: (2021)

Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS(G12C)-mutant cancer
por: Chiou, Li-Wen, et al.
Publicado: (2023)

Proteomic Mapping of the Interactome of KRAS Mutants Identifies New Features of RAS Signalling Networks and the Mechanism of Action of Sotorasib
por: Nolan, Aoife, et al.
Publicado: (2023)

Tolerability of sotorasib for KRAS positive lung adenocarcinoma patient with pre-existing interstitial pneumonia; A case report
por: Okada, Kohei, et al.
Publicado: (2023)

A Rare Event of Liver Dysfunction on Sotorasib and Management Strategy
por: Kinahan, Holly
Publicado: (2022)

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells
por: Jia, Yannan, et al.
Publicado: (2023)

Effect of peripheral cellular senescence on brain aging and cognitive decline
por: Budamagunta, Vivekananda, et al.
Publicado: (2023)

Correction to: Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer
por: Lee, Arnold
Publicado: (2022)

Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations
por: Lanman, Brian A., et al.
Publicado: (2022)

Sotorasib in KRAS(G12C) mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
por: Olivier, Timothée, et al.
Publicado: (2022)

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
por: Lv, Dongwen, et al.
Publicado: (2021)

Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
por: Negi, Arvind, et al.
Publicado: (2022)

PROTAC-DB 2.0: an updated database of PROTACs
por: Weng, Gaoqi, et al.
Publicado: (2022)

Severe Immune Checkpoint Inhibitor Hepatitis in KRAS G12C-Mutant NSCLC Potentially Triggered by Sotorasib: Case Report
por: Begum, Parvin, et al.
Publicado: (2021)

Sotorasib Shows Intracranial Activity in Patients with KRAS G12C-Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases
por: Koster, Kira-Lee, et al.
Publicado: (2022)

CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
por: Brazel, Danielle, et al.
Publicado: (2023)

Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma
por: Ramalingam, Prasanna Srinivasan, et al.
Publicado: (2023)

Complete response to sotorasib as neoadjuvant treatment in patient with locally advanced primary pulmonary sarcoma harboring KRAS mutation: a case report
por: Li, Ce, et al.
Publicado: (2022)

Activity of sotorasib against brain metastases from NSCLC harboring KRAS p.G12C mutation: a case report
por: Inno, Alessandro, et al.
Publicado: (2023)

PB2216: VACUOLES APPEAR IN RED BLOOD CELLS TRANSFUSED TO PATIENTS WITH SICKLE CELL DISEASE-RELATED HYPOSPLENISM
por: Dumas, L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o6b49sk8h2pvjmlk2ckpflnavu